Carmustine implants for the treatment of newly diagnosed high-grade gliomas: A cost-utility analysis

PharmacoEconomics

Volumn 26, Issue 1, 2008, Pages 33-44

  Rogers, Gabriel ^a   Garside, Ruth ^a   Mealing, Stuart ^a   Pitt, Martin ^a   Anderson, Rob ^a   Dyer, Matthew ^a   Stein, Ken ^a   Somerville, Margaret ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Carmustine polifeprosan 20 wafer, therapeutic use; Cost utility; Glioma, treatment

Indexed keywords

CARMUSTINE;

ANALYSIS OF VARIANCE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG IMPLANT; GLIOMA; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE; UNCERTAINTY;

EID: 37549034976     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826010-00004     Document Type: Article

References (53)

1. Souhami RL, Tannock I, Hohenberger P, et al. Oxford textbook of oncology. 2nd ed. Oxford: Oxford University Press, 2001
2. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet 2003; 361 (9354): 323-31
3. Dinnes J, Cave C, Huang S, et al. The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health Technol Assess 2001; 5 (13): 1-73
4. Berg G, Blomquist E, Cavallin-Stahl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 2003; 42 (5-6): 582-8
5. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002 Sep; 64 (3): 259-73
6. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005; 4 (7): 413-22
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002 Mar 23; 359 (9311): 1011-8
8. Walker MD, Alexander Jr E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978 Sep; 49 (3): 333-43
9. Solero CL, Monfardini S, Brambilla C, et al. Controlled study with BCNU vs CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979; 2 (1): 43-8
10. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980 Dec 4; 303 (23): 1323-9
11. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67 (2): 121-32
12. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas: a joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983 Sep 15; 52 (6): 997-1007
13. Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas: re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up. A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988; (6): 279-84
14. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-arterial chemotherapy. Neurology 1988 Feb; 38 (2): 284-9
15. Bashir R, Hochberg FH, Linggood RM, et al. Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme. J Neurosurg 1988 Jun; 68 (6): 917-9
16. Kleinschmidt-DeMasters BK, Geier JM. Pathology of high-dose intraarterial BCNU. Surg Neurol 1989 Jun; 31 (6): 435-43
17. Yang MB, Tamargo RJ, Brem H. Controlled delivery of 1,3-bis (2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate co-polymer. Cancer Res 1989 Sep 15; 49 (18): 5103-7
18. Brem H, Mahaley Jr MS, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J 1991 Mar; 74 (3): 441-6
19. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995 Nov; 26 (2): 111-23
20. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007; 11 (45): 1-242
21. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003 Apr; 5 (2): 79-88
22. Westphal M, Ram Z, Riddle V, et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006 Mar; 148 (3): 269-75
23. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors [report no. 5]. London: National Institute for Clinical Excellence, 2001
24. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
25. Barker FG, Prados MD, Chang SM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 1996 Mar; 84 (3): 442-8
26. Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg 2003 Sep; 99 (3): 458-66
27. CBTRUS: Central Brain Tumor Registry of the United States. Primary brain tumors in the United States: statistical report 1997-2001. Hinsdale (IL): CBTRUS, 2004 [online]. Available from URL: http://www.cbtrus.org/reports/2004- 2005/2005report.pdf [Accessed 2007 Nov 23]
28. US Food and Drug Administration. Approval package: gliadel wafer (20-637/S16). 2003 July 8 [online]. Available from URL: http://www.fda.gov/cder/ foi/nda/2003/20-637s016_Gliadel.htm [Accessed 2005 Jul 18]
29. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003 Jun; 98 (6): 1175-81
30. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 Mar 10; 352 (10): 987-96
31. Collett D. Modelling survival data in medical research. 2nd ed. Boca Raton (FL): Chapman & Hall, 2003
32. Department of Health. Reference costs 2004. London: Department of Health, 2005
33. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary no. 49 (March 2005). Wallingford: Pharmaceutical Press, 2005
34. Guest JF, Ruiz FJ, Russ J, et al. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK. Curr Med Res Opin 2005; 21: 271-80
35. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence, 2004
36. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997
37. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
38. NHS Value of Health Panel Project 2005 [online]. Available from URL: http://www.valueofhealth.org/ [Accessed 2005 Nov 2]
39. Osoba D, Aaronson NK, Muller M, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997 Sep; 34 (3): 263-78
40. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 Mar 3; 85 (5): 365-76
41. Osoba D, Aaronson C, Muller NK, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996; 5: 139-50
42. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: practical approach. Med Decis Making 1985; 5 (2): 157-77
43. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986 Apr; 6 (2): 85-92
44. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001 Dec; 10 (8): 779-87
45. Salo J, Niemela A, Joukamaa M, et al. Effect of brain tumour laterality on patients' perceived quality of life. J Neurol Neurosurg Psychiatry 2002 Mar; 72 (3): 373-7
46. Davies E, Clarke C, Hopkins A. Malignant cerebral glioma: II. Perspectives of patients and relatives on the value of radiotherapy. BMJ 1996 Dec 14; 313 (7071): 1512-6
47. Davies E, Hildebrand J. Communication, information and support for adults with malignant cerebral glioma: a systematic literature reveiw. Support Care Cancer 2003; 11: 21-9
48. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990 Jul; 8 (7): 1277-80
49. © [online]. Available from URL: http://curia.europa.eu/jurisp/cgi-bin/form.pl? lang=en&Submit-Submit&numaff-C-431/04 [Accessed 2007 Nov 23]
50. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 Oct 7; 90 (19): 1473-9
51. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7 (4): 839-45
52. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004 Jul 24; 329 (7459): 224-7
53. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence, 2004